Informações: Esta não é a versão mais recente do modelo de dados. Uma visão geral da versão pode ser encontrada à esquerda em Versões. Para a versão mais recente, clique aqui.
Informações:
Falhas:
ID
19262
Descrição
A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.; ODM derived from: https://clinicaltrials.gov/show/NCT00086320
Link
https://clinicaltrials.gov/show/NCT00086320
Palavras-chave
Versões (2)
- 16/12/2016 16/12/2016 -
- 16/12/2016 16/12/2016 -
Transferido a
16 de dezembro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Schizophrenia NCT00086320
Eligibility Schizophrenia NCT00086320
- StudyEvent: Eligibility
Similar models
Eligibility Schizophrenia NCT00086320
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Schizophrenia disease length
Item
dsm-iv diagnosis of schizophrenia at least 1 year before screening
boolean
C0036341 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0872146 (UMLS CUI [1,2])
schizophrenic episode Positive and negative syndrome scale
Item
experiencing an acute schizophrenic episode with a total panss score between 70 and 120
boolean
C1396838 (UMLS CUI [1,1])
C0451383 (UMLS CUI [1,2])
C0451383 (UMLS CUI [1,2])
Hospitalization Duration Agreement
Item
agree to be hospitalized for a minimum of 14 days at the start of the study
boolean
C0019993 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0680240 (UMLS CUI [1,3])
C0449238 (UMLS CUI [1,2])
C0680240 (UMLS CUI [1,3])
Investigational New Drugs Self-Administered Ability | Investigational New Drugs Administration Assistance Available
Item
capable of administering study medication themselves or have assistance with study medication administration consistently available throughout the study
boolean
C0013230 (UMLS CUI [1,1])
C1519231 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C1533734 (UMLS CUI [2,2])
C1269765 (UMLS CUI [2,3])
C0470187 (UMLS CUI [2,4])
C1519231 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C1533734 (UMLS CUI [2,2])
C1269765 (UMLS CUI [2,3])
C0470187 (UMLS CUI [2,4])
residence Address Same Continuous
Item
resided at the same address continuously for at least 30 days prior to screening
boolean
C0237096 (UMLS CUI [1,1])
C1442065 (UMLS CUI [1,2])
C0445247 (UMLS CUI [1,3])
C0549178 (UMLS CUI [1,4])
C1442065 (UMLS CUI [1,2])
C0445247 (UMLS CUI [1,3])
C0549178 (UMLS CUI [1,4])
Questionnaires Self-Administered Completion
Item
able and willing to fill out self administered questionnaires
boolean
C0034394 (UMLS CUI [1,1])
C1519231 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C1519231 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Washout Antiparkinson Agents | Washout Adrenergic beta-1 Receptor Antagonists
Item
washout of antiparkinsonian medications, beta-blockers
boolean
C1710661 (UMLS CUI [1,1])
C0003405 (UMLS CUI [1,2])
C1710661 (UMLS CUI [2,1])
C0304516 (UMLS CUI [2,2])
C0003405 (UMLS CUI [1,2])
C1710661 (UMLS CUI [2,1])
C0304516 (UMLS CUI [2,2])
Antiepileptic Agents | Lithium
Item
antiepileptics, lithium 3 days prior to the start of the run-in phase
boolean
C0003299 (UMLS CUI [1])
C0023870 (UMLS CUI [2])
C0023870 (UMLS CUI [2])
Axis I diagnosis | Schizophrenia
Item
dsm-iv axis i diagnosis other than schizophrenia
boolean
C0270287 (UMLS CUI [1])
C0036341 (UMLS CUI [2])
C0036341 (UMLS CUI [2])
Substance Dependence | Nicotine Dependence | Caffeine dependence
Item
dsm-iv diagnosis of substance dependence within 6 months prior to screening (nicotine and caffeine dependence are not exclusionary)
boolean
C0038580 (UMLS CUI [1])
C0028043 (UMLS CUI [2])
C1386553 (UMLS CUI [3])
C0028043 (UMLS CUI [2])
C1386553 (UMLS CUI [3])
Gastrointestinal stenosis Pathologic Severe Pre-existing | Gastrointestinal stenosis Iatrogenic Severe Pre-existing
Item
preexisting severe gastrointestinal narrowing (pathologic or iatrogenic)
boolean
C0521587 (UMLS CUI [1,1])
C1521733 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C2347662 (UMLS CUI [1,4])
C0521587 (UMLS CUI [2,1])
C0439669 (UMLS CUI [2,2])
C0205082 (UMLS CUI [2,3])
C2347662 (UMLS CUI [2,4])
C1521733 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C2347662 (UMLS CUI [1,4])
C0521587 (UMLS CUI [2,1])
C0439669 (UMLS CUI [2,2])
C0205082 (UMLS CUI [2,3])
C2347662 (UMLS CUI [2,4])
Injection of depot antipsychotic agent | paliperidone palmitate
Item
injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening
boolean
C2585377 (UMLS CUI [1])
C2719626 (UMLS CUI [2])
C2719626 (UMLS CUI [2])
Risperidone Psychotic Disorder | Poor response to treatment
Item
previous history of lack of response to risperidone when acutely psychotic
boolean
C0073393 (UMLS CUI [1,1])
C0033975 (UMLS CUI [1,2])
C1320680 (UMLS CUI [2])
C0033975 (UMLS CUI [1,2])
C1320680 (UMLS CUI [2])
Neuroleptic Malignant Syndrome
Item
history of neuroleptic malignant syndrome
boolean
C0027849 (UMLS CUI [1])
Suicidal behavior Risk Significant | Physical aggression Risk Significant
Item
significant risk of suicidal or violent behavior
boolean
C1760428 (UMLS CUI [1,1])
C0035647 (UMLS CUI [1,2])
C0750502 (UMLS CUI [1,3])
C0424323 (UMLS CUI [2,1])
C0035647 (UMLS CUI [2,2])
C0750502 (UMLS CUI [2,3])
C0035647 (UMLS CUI [1,2])
C0750502 (UMLS CUI [1,3])
C0424323 (UMLS CUI [2,1])
C0035647 (UMLS CUI [2,2])
C0750502 (UMLS CUI [2,3])